Navigation Links
Anthill Technologies Announces Agreement With Zafgen
Date:8/25/2008

WOBURN, Mass., Aug. 25 /PRNewswire/ -- Anthill Technologies, Inc. today announced that it has entered into an agreement with Zafgen, Inc. to apply its high-speed chemistry technologies and capabilities to Zafgen's obesity program. Zafgen, Inc. is a Boston-based biopharmaceutical company which develops obesity therapy based on the vascular targeting of adipose tissue.

Under the agreement, Anthill will use its ACOS(TM) high-speed synthesis and on-demand purification capabilities to assist Zafgen in the development of lead compounds for its obesity therapy programs. "We are very pleased to have the opportunity to assist Zafgen in its efforts to find novel and effective therapies to combat obesity," said Dr. Joseph C. Hogan Jr., CEO of Anthill Technologies. "We fully expect that our high-speed chemistry expertise and unique capabilities will help Zafgen to accelerate its obesity therapy discovery program."

Anthill Technologies, Inc. is pioneering the development and commercialization of high-speed chemistry technologies and systems for application across the chemical industry. Founded in 2005, the Company has developed and applied the first in a continuing series of high-speed chemistry systems, known as Applied Chemistry Operating Systems, or ACOS(TM), which are designed to dramatically reduce the time, cost and risks associated with discovering and developing chemical compositions, processes and products for both industrial and pharmaceutical applications. Additional information about Anthill Technologies is available on the Company's website at http://www.anthilltechnologies.com.


'/>"/>
SOURCE Anthill Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1

Related biology technology :

1. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
2. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
3. RF Technologies(R) Installs Safe Place(R) Solution for Pediatric and Infant Security at ProHealth Cares Waukesha Memorial Hospital
4. Reliant Technologies Announces Canadian Launch of Fraxel re:pair(R) Laser: A New Class of Treatment Therapy for CO2 Laser Skin Resurfacing
5. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
6. RainDance Technologies Appoints Olex Vice President, System Development
7. BioSpecifics Technologies Corp. Reports Second Quarter 2008 Financial Results
8. Mark C. Mirken Named New CEO and Chairman of the Board of Millennium Biotechnologies, Inc.
9. ImmunoVaccine Technologies Broadens Its Patent Protection to Japan
10. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
11. MaxWell Biocorporation, LLC, and International Medical Information Technologies, Inc., Announce Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6